Linagliptin Tablets (Tradjentaâ„¢)

Elliott, William T.; Chan, James
July 2011
Internal Medicine Alert;7/29/2011, Vol. 33 Issue 14, p110
The article reports on the approval of Boehringer Ingelheim GmbH's Tradjenta linagliptin tablet for the treatment of type 2 diabetes mellitus by the U.S. Food and Drug Administration (FDA).


Related Articles

  • US Approves Aptivus.  // Guide;Aug2005, Vol. 25 Issue 8, p47 

    Reports on the approved protease inhibitor Aptivus from Boehringer Ingelheim by the U.S. Food and Drug Administration. Availability of the drug in pharmacies; Therapeutic features of the drug; Capacity of the drug to treat adults with drug-resistant HIV.

  • Embracing the new terrain. Arnold, Matthew // Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p34 

    The article focuses on the achievements of privately German owned company Boehringer Ingelheim (BI) GmbH which has continually produces safe and reliable products. It highlights the move of the company to invest and expand in the U.S. market. Furthermore, the approval given by the Food and Drug...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;May2008 Pharmacology Watch, p2 

    The article reports on two actions taken by the U.S. Food & Drug Administration (FDA) as of May 2008. An early communication was issued by the FDA about an ongoing safety review of tiotropium, an inhaler from Boehringer Ingelheim for bronchospasm associated by chronic obstructive pulmonary...

  • Boehringer Ingelheim: US nod for Mirapex ER but future is brighter in Europe.  // PharmaWatch: Monthly Review;Apr2010, Vol. 9 Issue 4, p13 

    In this article, the author discusses the approval of the U.S. Food and Drug Administration (FDA) on Mirapex extended-release (ER) tablets of Boehringer Ingelheim GmbH. He states that the drug has been proven in clinical trials to significantly improve the daily life aspects of patients with...

  • 14 BOEHRINGER-INGELHEIM.  // Contract Pharma;Jul/Aug2011, Vol. 13 Issue 6, p95 

    The article focuses on pharmaceutical company Boehringer Ingelheim GmbH (BI) headquartered in Ingelheim am Rhein, Germany. It mentions that the company suffered a decline in revenue because of the weakening Euro and the loss of patent protection for Flomax and Mirapex. It notes that is shifting...

  • Generic Drugs for Osteoarthritis.  // FDA Consumer;Nov/Dec2006, Vol. 40 Issue 6, p8 

    The article reports on the approval of several generic versions of Boehringer Ingelheim's Mobic or meloxicam tablets by the U.S. Food and Drug Administration (FDA). The approval of meloxicam was the result of a cluster review approach, one of the process improvements the FDA has instituted to...

  • New products.  // Drug Topics;Nov2015, Vol. 159 Issue 11, p66 

    The article previews several drugs that have received approval from the Food and Drug Administration (FDA) including Boehringer Ingelheim's idarucizumab (Praxbind) 5-g injection, patiromer for oral suspension (Veltassa) and buccal buprenorphine HCl (Belbuca).

  • FDA approves equine pergolide product. Barakat, Christine; McCluskey, Mick // Equus;Jan2012, Issue 412, p10 

    The article discusses the U.S. Food and Drug Administration's (FDA) approval of pergolide for horses. It states that pergolide was used to treat people with Parkinson's disease, and in some cases, for horses afflicted with pituitary pars intermedia dysfunction (PPID). In 2007, however, it...

  • Drug update.  // Cortlandt Forum;3/25/2004, Vol. 17 Issue 3, p18 

    Introduces several drugs newly approved for marketing by the U.S. Food and Drug Administration. Efficacy of Spiriva HandiHaler, a tiotropium bromide inhalation powder manufactured by Boehringer Ingelheim GmbH, for the treatment of chronic obstructive pulmonary disease; Action of Uroxatral...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics